Toronto - Telo Genomics Corp. (TSX-V: TELO) (OTCQB: TDSGF) (the 'Company' or 'Telo') announces that it has closed its previously announced non-brokered private placement ('Offering') of units (the 'Units').
The Company issued a total of 11,335,500 Units at a price of $0.25 per Unit for gross proceeds of $2,833,875. Each Unit issued consisted of one common share of the Company (a 'Common Share') and one-half of one non-transferable common share purchase warrant (each whole warrant, a 'Warrant'). Each Warrant will entitle the holder to acquire one additional Common Share at a price of $0.40 per Common Share until June 13, 2025.
In connection with the Offering, the Company paid a total of $173,503.75 finder's fees in cash and issued a total of 694,015 finder's warrants (the 'Finder's Warrants') to arm's length finders. Each Finder's Warrant entitles the holder to acquire one common share of the Company at a price of $0.25 per share until June 13, 2024. The Company intends to use the net proceeds of the Offering to fund its commercial plan to launch the Company's lead product for smoldering multiple myeloma, the Company's ongoing collaborative studies with the Mayo Clinic in multiple myeloma, to achieve the ISO 15189 certification and the certified Clinical Laboratory Improvement Amendments (CLIA) accreditation, and for general working capital purposes. The securities issued pursuant to the Offering are subject to a statutory four month hold period ending on October 14, 2023 in accordance with applicable securities laws.
The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.
Contact:
Kris Weinberg
Tel: 678-429-5582
Email: kris.weinberg@telodx.com
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute 'forward-looking information' under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward looking terminology such as 'will', or variations of such words and phrases or statements that certain actions, events or results 'will' occur. Forward-looking statements regarding the Offering, the use of proceeds, and receipt of final approval from the TSX Venture Exchange are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward looking information that are incorporated by reference herein, except as required by applicable securities laws.
TELO GENOMICS CORP. 
